- Home
- BNC vs XFOR Comparison
BNC vs XFOR Comparison
Compare BNC & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNC
- XFOR
- Stock Information
- Founded
- BNC N/A
- XFOR 2014
- Country
- BNC United States
- XFOR United States
- Employees
- BNC N/A
- XFOR N/A
- Industry
- BNC Industrial Machinery/Components
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BNC Industrials
- XFOR Health Care
- Exchange
- BNC Nasdaq
- XFOR Nasdaq
- Market Cap
- BNC 13.7M
- XFOR 11.3M
- IPO Year
- BNC N/A
- XFOR N/A
- Fundamental
- Price
- BNC $27.34
- XFOR $1.42
- Analyst Decision
- BNC
- XFOR Strong Buy
- Analyst Count
- BNC 0
- XFOR 3
- Target Price
- BNC N/A
- XFOR $72.33
- AVG Volume (30 Days)
- BNC 1.0M
- XFOR 1.9M
- Earning Date
- BNC 08-22-2025
- XFOR 08-19-2025
- Dividend Yield
- BNC N/A
- XFOR N/A
- EPS Growth
- BNC N/A
- XFOR N/A
- EPS
- BNC N/A
- XFOR N/A
- Revenue
- BNC $3,478,254.00
- XFOR $32,774,000.00
- Revenue This Year
- BNC N/A
- XFOR $1,300.08
- Revenue Next Year
- BNC N/A
- XFOR N/A
- P/E Ratio
- BNC N/A
- XFOR N/A
- Revenue Growth
- BNC 10.08
- XFOR 5721.31
- 52 Week Low
- BNC $5.60
- XFOR $1.35
- 52 Week High
- BNC $82.88
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- BNC N/A
- XFOR 36.14
- Support Level
- BNC N/A
- XFOR $1.54
- Resistance Level
- BNC N/A
- XFOR $1.73
- Average True Range (ATR)
- BNC 0.00
- XFOR 0.21
- MACD
- BNC 0.00
- XFOR 0.02
- Stochastic Oscillator
- BNC 0.00
- XFOR 7.78
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.